|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
These data highlight the importance of CD14++ monocytes in cardiovascular diseases.
|
31055050 |
2020 |
|
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Effect of CD14 polymorphisms on the risk of cardiovascular disease: evidence from a meta-analysis.
|
30922395 |
2019 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
We believe that blockade of CD14 on the cell surface and clinical use of anti-CD14 mAbs or their Fab fragments may diminish the production of ROS and improve outcomes during cardiovascular diseases manifested by LPS-induced inflammation.
|
30944694 |
2019 |
|
Cardiovascular Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
However, in multivariable models adjusted for cardiovascular disease risk factors, lower absolute levels of soluble CD14 and interleukin 6 and greater declines in the CD14 level and kynurenine-tryptophan ratio after 6 months of ART predicted a lower CCIMT years later (P < .01).
|
26347573 |
2016 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Given the relationship between innate immune activation and CVD, we investigated the association of single-nucleotide polymorphisms (SNPs) in TLR4 and CD14 and carotid intima-media thickness (cIMT), a surrogate measurement for CVD, in HIV-infected individuals on ART and HIV-uninfected controls as a cross-sectional, case-control study.
|
27495090 |
2016 |
|
Cardiovascular Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Psoriasis patients exhibit an increased risk of death by cardiovascular disease (CVD) and have elevated levels of circulating intermediate (CD14(++)CD16(+)) monocytes.
|
26223654 |
2015 |
|
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The CD14 C-260T SNP was associated with increased monocyte activation but not systemic inflammation or cIMT in this HIV-infected cohort with low CVD risk profile.
|
25622527 |
2015 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Monocyte surface markers CD14 ⁺⁺and CD16⁺ have been established as biomarkers for increased cardiovascular disease risk in a large number of studies.
|
23739627 |
2013 |
|
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
All the case-control association studies evaluating the role of CD14 C260T in CVD were identified.
|
19433913 |
2009 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
CD14 may be a factor in the pathophysiology of COPD, as it is in asthma and smoking-related cardiovascular diseases.
|
19361972 |
2009 |
|
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
To assess if T to C exchange at position 159 of the CD14 gene correlates with age at the onset of first myocardial infarction (MI), severity of coronary atherosclerosis and number of risk factors in MI survivors in a local community characterised by high morbidity of cardiovascular diseases and whether this genotyping could be helpful in identifying patients with a high risk of MI at young age and beyond low number of risk factors.
|
17436151 |
2007 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The evolutive advantages of increased inflammatory responses, hypersecretion of proinflammatory cytokines [tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-1beta, IL-6, and IL-18], or decreased anti-inflammatory molecules (adiponectin, certain TNF-alpha isoforms, soluble CD14, etc.), would lead in westernized countries to chronic inflammation conditions, such as obesity and type 2 diabetes, resulting in cardiovascular disease.
|
16472051 |
2006 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
We also measured the concentration of serum soluble CD14 and the density of membranous CD14 on monocytes in the CVD patients, but the polymorphism was not associated with either the concentration of soluble CD14 or the density of membranous CD14 (P:=0.358, P:=0.238, respectively).
|
11062291 |
2000 |